WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients

A logo is pictured outside a building of the World Health Organization (WHO) during an executive board meeting on update on the coronavirus disease (COVID-19) outbreak, in Geneva, Switzerland, April 6, 2021. REUTERS/Denis Balibouse/File Photo
  • Trial of drugs to take place in 52 countries
  • Search is for medicines to save lives of COVID-19 victims

ZURICH, Aug 11 (Reuters) - The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.

"These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients," it said in a statement on the Solidarity PLUS trial.

The trial involves thousands of researchers at more than 600 hospitals, WHO Director General Tedros Adhanom Ghebreyesus told a news briefing from Geneva.

Register now for FREE unlimited access to Reuters.com

Finland is one of the first countries to enroll patients in the Solidarity PLUS trial, he added.

"There are many variants, and all variants can appear anywhere on the planet. And so having so many sites in so many different countries and regions will help us get to these answers as fast as possible," said Marie Pierre Preziosi, co-lead of the research and development blueprint at the WHO.

Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.

The WHO warned countries to come together to combat the fast-spreading Delta variant of the coronavirus and urged equitable access to essential countermeasures.

"At the current trajectory, we could pass 300 million reported cases early next year. But we can change that. We’re all in this together, but the world is not acting like it," Tedros said.

The WHO last week called for a halt on COVID-19 vaccine boosters until at least the end of September as the gap between vaccinations in wealthy and poor countries widens. read more

The original Solidarity trial last year found that all four treatments evaluated - remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon - had little or no effect in helping COVID patients. The WHO expects final results from this trial next month.

So far, only corticosteroids have been proven effective against severe and critical COVID-19.

The WHO said artesunate, produced by Ipca (IPCA.NS), is used to treat malaria. In the trial, it will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Imatinib, produced by Novartis (NOVN.S), is used to treat certain cancers. In the trial, it will be administered orally, once daily, for 14 days.

Infliximab, produced by Johnson and Johnson (JNJ.N), is used to treat diseases of the immune system. In the trial, it will be administered intravenously as a single dose.

Register now for FREE unlimited access to Reuters.com
Reporting by Michael Shields and Dania Nadeem Editing by Jason Neely and Mark Potter

Our Standards: The Thomson Reuters Trust Principles.

Thomson Reuters

Switzerland and Austria bureau chief leading a multimedia team of journalists based in Zurich, Geneva and Vienna covering Swiss and Austrian spot news, features, pictures and video with experience reporting from dozens of countries on three continents since 1987.